EUVIMEDEUVIMED entdecken
Multizentrische Studie

Real-world drug monitoring of dalbavancin using a three-dose regimen of 1500 mg at days 1, 15 and 43 in bone and joint or cardiovascular infection

Thomas Lin, Eric Senneville iD, Benjamin Hennart, Benjamin Valentin iD, Barthelemy Lafon-Desmurs, Anne Boucher, Maxime Pradier, Pierre Patoz, Olivier Robineau iD, Benoit Gachet iD

Journal of Antimicrobial Chemotherapy · 02.02.2026 · 81 (3)

DOI: 10.1093/jac/dkag039 ↗

Kurz gefasst

Multizentrische Studie in der Zeitschrift Journal of Antimicrobial Chemotherapy, online erschienen am 13.02.2026. Verfasst von Thomas Lin und 9 weiteren Autor:innen. Beteiligte Einrichtung: Infectious Diseases Department, Gustave Dron Hospital, Tourcoing, France. Hauptthemen laut MEDLINE: Anti-Bacterial Agents, Drug Monitoring, Gram-Positive Bacterial Infections, Teicoplanin. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 18 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Dalbavancin is a promising option for the treatment of complex gram-positive infections. However, the optimal dosing regimen to ensure adequate drug exposure during prolonged treatment courses remains debate.

Objectives

To evaluate whether an intravenous dalbavancin regimen of 1500 mg administered on days 1, 15 and 43 achieves validated serum concentration targets for infections requiring 12 weeks of treatment.

Methods

We conducted a retrospective bicentric study including patients who received three 1500 mg doses of dalbavancin intended to provide 12 weeks of treatment coverage between January 2020 and May 2024. Patients’ characteristics, microbiological data, and dalbavancin concentrations measured before reinjection on days 15, 43 and 90 were collected. We targeted a total dalbavancin plasma concentration of ≥8.04 mg/L, validated for Staphylococcus spp. strains with a MIC ≤0.125 mg/L. Concentrations were compared according to body mass index (≥30 kg/m2) and albumin level (≥30 g/L).

Results

Forty-two patients (39 bone and joint infections and three vascular infections) were included. Dalbavancin serum trough concentrations exceeded 8.04 mg/L for all available measurements (76/76) across the different monitored time points during the 12-week treatment period. Although lower concentrations were observed in patients with hypoalbuminemia or obesity, all measured values remained above the target threshold.

Conclusions

These results suggest that a three-dose dalbavancin regimen administered on days 1, 15, and 43 may achieve validated pharmacokinetic targets and maintain therapeutic exposure over a 12-week period for staphylococcal infections with a dalbavancin MIC ≤0.125 mg/L. Therapeutic drug monitoring should be performed for patients with hypoalbuminemia or obesity until larger studies confirm these findings, and for strains with an MIC >0.125 mg/L.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Anti-Bacterial AgentsDrug MonitoringGram-Positive Bacterial InfectionsTeicoplaninAgedAged, 80 and overFemaleHumansMaleMiddle AgedMicrobial Sensitivity TestsRetrospective StudiesStaphylococcus

Substanzen

Anti-Bacterial AgentsdalbavancinTeicoplanin

Autor:innen und Institutionen

  • Infectious Diseases Department, Gustave Dron Hospital, Tourcoing, France.
  • Département of Biostatistics, ULR 2694 METRICS Evaluation des technologies de santé et des pratiques médicales, Gustave Dron Hospital, University of Lille, Lille, France.
  • Toxicology Unit, Biology and Pathology Center, Lille University Hospital, Lille, France.
  • Pharmacy Institute, Lille University Hospital, Lille, France.
  • Department of Microbiology, Gustave Dron Hospital, Tourcoing, France.
  • Institut Pierre Louis d'Epidémiologie et de Santé Publique, UMR-S 1136, INSERM, AP-HP, Paris, France.

ORCID-Profile: Eric Senneville, Benjamin Valentin, Olivier Robineau, Benoit Gachet

Zitieren

APA

Lin, T., Senneville, E., Hennart, B., Valentin, B., Lafon-Desmurs, B., Boucher, A., Pradier, M., Patoz, P., Robineau, O., & Gachet, B. (2026). Real-world drug monitoring of dalbavancin using a three-dose regimen of 1500 mg at days 1, 15 and 43 in bone and joint or cardiovascular infection. Journal of Antimicrobial Chemotherapy, 81(3). https://doi.org/10.1093/jac/dkag039

Vancouver

Lin T, Senneville E, Hennart B, Valentin B, Lafon-Desmurs B, Boucher A, et al. Real-world drug monitoring of dalbavancin using a three-dose regimen of 1500 mg at days 1, 15 and 43 in bone and joint or cardiovascular infection. Journal of Antimicrobial Chemotherapy. 2026;81(3). doi:10.1093/jac/dkag039

BibTeX
@article{Lin2026,
  author = {Lin, Thomas and Senneville, Eric and Hennart, Benjamin and Valentin, Benjamin and Lafon-Desmurs, Barthelemy and Boucher, Anne and Pradier, Maxime and Patoz, Pierre and Robineau, Olivier and Gachet, Benoit},
  title = {Real-world drug monitoring of dalbavancin using a three-dose regimen of 1500 mg at days 1, 15 and 43 in bone and joint or cardiovascular infection},
  journal = {Journal of Antimicrobial Chemotherapy},
  year = {2026},
  volume = {81},
  number = {3},
  doi = {10.1093/jac/dkag039}
}
Kostenlos starten →